US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

Endo International plc, et al.

Track this case

Case Number:

7:22-bk-22549

Court:

New York Southern

Nature of Suit:

Firms

Companies

Government Agencies

Sectors & Industries:

  1. June 01, 2026

    Endo Trust's $4B Claim Vs. TPG Units Survives Dismissal Bid

    Affiliates of TPG Capital must face a lawsuit seeking to claw back $4.1 billion they made from the sale of a generic opioid manufacturer to Endo International PLC, whose trustee has alleged it did not receive reasonably equivalent value in the deal.

  2. September 30, 2025

    McKinsey Trims Endo Suit But Can't Nix Indemnification Claim

    A New York bankruptcy judge trimmed an adversary suit Monday claiming McKinsey & Co. Inc. should pay at least $1.5 billion to cover costs bankrupt pharmaceutical developer Endo International racked up defending against opioid claims, tossing nearly all allegations with leave to amend, but greenlighting an indemnification claim.

  3. April 02, 2025

    PE Firm TPG Wants Endo Trust's Transfer Suit Tossed

    Private equity firm TPG Capital is seeking the dismissal of a lawsuit that aims to claw back billions of dollars reaped in an allegedly unfair deal with Endo International PLC before the drugmaker went bankrupt.

  4. August 19, 2024

    TPG Dumped Opioid Co. On 'Unsuspecting' Endo, Suit Says

    After pushing Par Pharmaceutical to grow its market share in generic opioids and disregard federal requirements to report suspicious orders, TPG Capital saw other opioid manufacturers being inundated with litigation and sold Par to "an unsuspecting" Endo International PLC, according to a lawsuit filed in New York bankruptcy court.

  5. August 16, 2024

    McKinsey Drove Opioid Sale Scheme, Endo Ch. 11 Trust Says

    Consulting giant McKinsey & Co. should pay at least $1.5 billion to cover costs pharmaceutical developer Endo International racked up defending against claims that it helped drive the opioid crisis, an unsecured creditors' trustee has said, telling a New York bankruptcy judge the consultant's marketing and sales advice lit a "ticking time bomb" that sent Endo into Chapter 11.

  6. April 22, 2024

    Endo Creditor Trust Asks For $50M In Litigation Financing

    The committee of unsecured creditors in the Chapter 11 case of pharmaceutical company Endo International asked a New York bankruptcy judge Monday for permission to enter into a $50 million secondary financing facility to help the creditor trust created under the company's bankruptcy plan pursue litigation and settlements of potential claims.

  7. March 20, 2024

    Endo Plan To Trim $5B In Debt Confirmed By NY Judge

    Drugmaker Endo International got a New York bankruptcy judge's approval for its Chapter 11 plan that aims to cut more than $5 billion in debt and hand over ownership to its lenders, roughly a month after it finalized a $465 million deal to resolve criminal and civil opioid claims.

  8. February 29, 2024

    Bankrupt Endo To Pay $465M To Resolve Opioid Claims

    Drugmaker Endo International has agreed to pay as much as $465 million to resolve criminal and civil claims stemming from its sale and marketing of a powerful opioid, and will turn over its assets to a group of secured lenders who will operate the company under a new corporate structure.

  9. February 02, 2024

    Drugmaker Endo Wants To Extend Opioid Suit Pause

    Endo has asked a New York bankruptcy judge to pause the opioid litigation leveled against it for five more months, asserting that the pharmaceutical company made "wide-ranging progress" in its Chapter 11 case and expects to have a reorganization plan confirmed by March.

  10. September 21, 2023

    Skadden Nabs $19M Fee For 4 Months' Work On Endo Ch. 11

    Skadden Arps Slate Meagher & Flom LLP was cleared Thursday by a New York judge to be paid over $19 million for its work from January to April 2023 on the Chapter 11 bankruptcy of pharmaceutical company Endo International PLC.